JP Morgan Maintains Overweight on Ascendis Pharma, Raises Price Target to $170
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Jessica Fye maintains an Overweight rating on Ascendis Pharma (ASND) and raises the price target from $167 to $170.
May 03, 2024 | 3:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan analyst Jessica Fye maintains an Overweight rating on Ascendis Pharma and raises the price target from $167 to $170.
The increase in price target by JP Morgan reflects a positive outlook on Ascendis Pharma's stock, suggesting potential upside. This analyst action can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100